'Psyched': Havn Life Goes Public, CannaGlobal Inks Merger, Numinus Raises CA$4.6M

Havn Life Goes Public on CSE and Announces Authorization for Research 

Havn Life Sciences Inc. (CSE : HAVN), a recently-formed psychedelics company, announced on Tuesday its debut on the Canadian Securities Exchange under the symbol HAVN.

The company is led by co-CEOs Susan Chapelle and Tim Moore, the former CEO of cannabis company Green Growth Brands Inc.

Other supporters include Vic Neufeld, former CEO of Aphria APHA, who serves as director of the board. The board also includes Canada’s former deputy prime minister Sheila Copps.

Formed in June of 2020, Havn defines itself as a biotechnology company focused on “unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi.”

The company operates a research facility located in the South Campus at The University of British Columbia.

“We are currently working on a variety of projects including product formulation of effective microdosing of novel psychoactive compounds as well as the development of a state-of-the-art mycology lab for extraction,” said Chapelle.

On Thursday, the company also announced that its wholly owned subsidiary, HAVN Research Inc., was granted a Section 56 exemption by Health Canada. This gives Havn the ability to possess certain amounts of pure psilocybin for scientific purposes.

With this authorization, Havn will begin to work on experiments with the aim of developing methods for the safe, standardized, quality-controlled production of psilocybin.

Numinus Closes CA$4.6M Offering

Vancouver-based psychedelics company Numinus NUMI announced the closing of an oversubscribed offering of shares for CA$4.6 Million ($3.5 million).

The company said it plans to use the proceeds to develop MDMA and psilocybin treatment implemented under the Compassionate Access protocol of Health Canada.

The funds will also be used to secure therapy space, develop psychedelic integrative treatment models and upgrade the company’s Lab infrastructure.

CannaGlobal Enters Psychedelics Market Via Merger

Cannabis company CannaGlobal Canada Co. announced the definitive closing of a merger with psychedelics companies Sansero Life Sciences and Rise Wellness, giving birth to CannaGlobal Wellness.

Initial news of the merger were made available in July.

Steve Sadoff, co-founder of Sansero, Canadian psilocybin research company, will serve as CEO. 

The venture, which will retain the name CannaGlobal Wellness until a new one is set, will focus on the development of novel pharmaceuticals to work as replacements for antidepressants and stimulants for ADHD, with psilocybin as a main compound.

Lorne Gertner, founder of CannaGlobal will also be involved in the company as chairman. Gertner is a cannabis industry veteran who co-founded Tokyo Smoke, later sold to Canopy Growth CGC for CA$250 million ($189 million), and was also involved in the early start of Cronos Group.

Rise Wellness, the third and last participant of the merger, is a company that offers psilocybin therapy retreats in Jamaica.